Drugs / IMC-C103C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03973333 | May 2019 → Sep 2023 | cancer | Immunocore Ltd | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-12-08 | Immunocore Ltd | Results Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4 immunocore.com ↗
Reductions in ctDNA were observed in over half of ctDNA evaluable patients (12/22), including 7 with ≥ 50% reductions, and even in those with low or zero MAGE-A4 expression. |
| 2021-12-06 | Immunocore Ltd | Results Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4 immunocore.com ↗
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 6 December 2021) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid tumors. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-08 | Immunocore Ltd | Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4 immunocore.com ↗ |
| 2021-12-06 | Immunocore Ltd | Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4 immunocore.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-C103C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03973333 ↗ |
| Modality | Protein / enzyme biologic | “IMC-C103C is an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC ®)” NCT03973333 ↗ |
| Route | Intravenous | “administered intravenously (IV) and subcutaneously (SC) once weekly (Q1W)” NCT03973333 ↗ |
| Route | Subcutaneous | “administered intravenously (IV) and subcutaneously (SC) once weekly (Q1W)” NCT03973333 ↗ |